Abbott Laboratories (ABT) Stock: Price, Forecast & Analyst Target
Abbott Laboratories (ABT) — MoonshotScore 71/100 (Strong band), calculated Nov 22, 2026. Price $103.00 (-0.84%), as of the Nov 20, 2026 trading session; market cap $178B. Expected results Jan 28, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 41.41× (market value Nov 22, 2026; cash Sep 30, 2026) · expected results Jan 28, 2027
Abbott Laboratories · ABT · NYSE · Healthcare · Medical - Devices
Research dated 2026-09-12: Abbott Laboratories sells medical devices, diagnostic systems and tests, nutritional formulas, and established medicines; its results therefore reflect several distinct healthcare demand engines rather than a pure device cycle. The case now hinges on whether rising sales can again produce rising operating earnings while expenses absorb more gross profit and the cash balance moves lower.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Abbott Laboratories (ABT)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Full; Growth Durability: Growing; Momentum: Rising.
- EPS beat 0 of the last 4 reports
- expected results Jan 28, 2027
- Altman Z 3.28 · Piotroski F 6
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 72 | Strong | |
| 72 | Strong | |
| 72 | Strong | |
| 69 | Strong | |
| 69 | Strong | |
| 69 | Strong |
The score moved from 69 in the stored Nov 21, 2026 snapshot to 71 in the current publication computed Nov 22, 2026 (+2); the largest pillar moves were Momentum +5 and Valuation -2. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $103.00 | |
| Change on the day | -0.84% | |
| 52-week range | $81.97–$129.85 | |
| Market capitalisation | $178B | |
| Price / earnings (trailing) | 38.15 | |
| Shares traded on the day | 7.29M | |
| Beta (volatility vs the S&P 500) | 0.54 |
Why Abbott Laboratories scores 71
Share price, last 12 months -13.9%
$127.00 $109.35
What the price assumes
10.9% a year of free-cash-flow growth for ten years is what a $178.00B market value () asks for.
The price already assumes faster growth than the last 5 years delivered. Anything short of an acceleration leaves room to disappoint. It also runs ahead of the analysts' revenue path.
Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $6.76B. Inputs: FMP statements, estimates and quote.
How the stock reacts to earnings
EPS beat in 4 of the last 12 reports (2024–2026); the stock still fell the next session after 2 of those beats. Average first-session move: 4.8% either way.
- -1.4%Jan ’24
- -3.6%Apr ’24
- -2.5%Jul ’24
- +1.6%Oct ’24
- +5.5%Jan ’25
- +3.8%Apr ’25
- -6.1%Jul ’25
- -4.2%Oct ’25
- -11.0%Jan ’26
- -4.7%Apr ’26
- +12.8%Jul ’26
- +0.1%Oct ’26
Every report, with revenue and five-session moves
| Report | EPS | Revenue | Next session | 5 sessions |
|---|---|---|---|---|
| In line | In line | +0.1% | +0.2% | |
| Beat | In line | +12.8% | +12.9% | |
| In line | Beat | -4.7% | -8.9% | |
| In line | Miss | -11.0% | -12.1% | |
| In line | In line | -4.2% | -4.0% | |
| In line | In line | -6.1% | -4.6% | |
| Beat | In line | +3.8% | +2.5% | |
| In line | In line | +5.5% | +9.5% | |
| In line | In line | +1.6% | +0.8% | |
| Beat | In line | -2.5% | +1.2% | |
| Beat | In line | -3.6% | -2.1% | |
| In line | In line | -1.4% | -0.7% |
Beating the estimate has not been enough: the stock fell after 2 of the last 4 beats. The bar it has to clear is the whisper number, not the published one.
Our track record on this stock
Since the score went from 70 to 69 while the share price moved -11.7% through .
The score has stayed in the Strong band across the stretch we have recorded; we grade each band change three months after it happens.
The crowd against our signals
- Analysts: 77% of 43 rate it a buy; the average target ($120.85, captured ) sits +17.3% from the price of $103.00.
- Last 90 days: 1 upgrade and 1 downgrade among 15 rating actions.
- Our signals: Strong band; strongest pillar Business Quality (81), weakest Financial Safety (42).
Here we and the crowd agree.
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Abbott Laboratories (ABT): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 22, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 22, 2026, except a card that shows its own read date.
What is Abbott Laboratories (ABT), and what does it report?
Short answer · as of
Abbott earns revenue when hospitals and laboratories buy testing platforms, cartridges and automation; when clinicians use cardiovascular, diabetes and neuromodulation products; and when consumers or healthcare channels buy nutritional formulas and established generic medicines.
Research dated 2026-09-12.
Medical Devices is the largest reporting segment, but Diagnostics, Nutrition, and Established Pharmaceutical Products make consolidated revenue a measure of several different purchasing patterns.
That mix corrects the obvious reading of Abbott as simply a device maker. A movement in total sales may reflect procedure-related devices, recurring diagnostic consumption, nutrition demand, medicine volumes, or several of these at once, so the segment composition matters as much as the headline.
What do the latest results show for Abbott Laboratories (ABT)?
Research dated 2026-09-12.
The latest quarter delivered the strongest revenue and gross profit in the reported sequence, yet operating profit fell from the preceding period and net income and diluted earnings weakened. Selling, general and administrative expense rose sharply while research and development spending also increased, absorbing more than the added gross profit; this was a reversal in operating leverage, not a contraction in revenue.
Recent reported results cleared prevailing revenue and earnings estimates, while management framed the near-term outlook through an adjusted earnings range. That distinction matters because the income statement shows weaker reported profit conversion even as the expectation record and management outlook emphasize adjusted earnings.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $13.01B Sep 30, 2026
- Latest quarter · R&D
- $920.00M Sep 30, 2026
- Latest quarter · SG&A
- $4.27B Sep 30, 2026
- Latest quarter · FMP standardized operating result
- $1.36B Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $13.01B | $920.00M | $4.27B | $1.36B |
| Mar 31, 2026 | $11.16B | $767.00M | $3.74B | $1.34B |
| Dec 31, 2025 | $11.46B | $735.00M | $3.13B | $2.25B |
| Sep 30, 2025 | $11.37B | $766.00M | $3.05B | $2.06B |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Jun 2025 | $11.14B | $1.78B | $0.00 (diluted) |
| Sep 2025 | $11.37B | $1.64B | $0.94 (diluted) |
| Q4 FY2025 | $11.46B | $1.78B | $1.01 (diluted) |
| Q1 FY2026 | $11.16B | $1.08B | $0.61 (diluted) |
What are the financial strengths and risks for Abbott Laboratories (ABT)?
Short answer
Cash and short-term investments were $4.30B at the Sep 30, 2026 balance-sheet date. Operating cash flow was $1.74B for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-12.
Operating cash flow has remained positive throughout the reported quarterly sequence and strengthened in the latest period, giving Abbott internally generated funds despite weaker reported earnings. Liquidity ratios remain workable, and the available distress screen does not signal immediate balance-sheet strain.
Debt nevertheless stands far above cash and investments, leaving Abbott in a net-debt position. Cash and short-term investments have declined across the reported window, including consecutive drops from the recent peak, so sustained expense growth, weaker profit conversion, or a retreat in operating cash flow would reduce financial flexibility.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Rich valuation — a P/E of 38.15 runs well above the Healthcare sector’s ~20.60x, leaving little room for a miss.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $1.74B Sep 30, 2026
- Previous quarter · operating cash flow
- $1.31B Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $1.74B | −$513.00M |
| Mar 31, 2026 | $1.31B | −$399.00M |
| Dec 31, 2025 | $3.31B | −$689.00M |
| Sep 30, 2025 | $2.79B | −$496.00M |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Abbott Laboratories (ABT)?
Short answer · as of
The next earnings report is expected on Jan 28, 2027.
Research dated 2026-09-12.
The next earnings release should be read through revenue quality and conversion: whether sales remain near the recent high, whether operating profit resumes growing with gross profit, and whether selling and administrative costs retreat from their latest step-up. Reported adjusted earnings can then be compared with management’s stated range and the prevailing estimate, while revenue can be tested against the market’s expected expansion.
Cash is the other live check. A rebound in cash and short-term investments alongside continued operating cash generation would ease the tension between healthy cash inflow and the declining balance; another drop would keep attention on uses of cash and the gap between debt and liquidity.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Abbott Laboratories compare with its peers?
Short answer
Abbott Laboratories's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
A focused medical-device company rises and falls mainly with adoption of its devices and the clinical activity that supports their use. Abbott also sells laboratory systems and consumable tests, pediatric and adult nutrition, and established medicines, so consolidated performance combines institutional, clinical, and consumer demand.
Medical Devices remains the largest segment, but Diagnostics and Nutrition are substantial businesses in their own right. This breadth can keep weakness in a particular healthcare category from defining the entire company, while also making group revenue a less precise indicator of device execution than it would be for a specialist.
| Company | Price | Market value | Score |
|---|---|---|---|
| $101.85 Nov 20, 2026 | $58.6B | 94 5-pillar Nov 22, 2026 | |
| $79.32 Nov 20, 2026 | $29.6B | 93 5-pillar Nov 22, 2026 | |
| $319.12 Nov 20, 2026 | $12.6B | 93 5-pillar Nov 22, 2026 | |
| $255.76 Nov 20, 2026 | $24.8B | 88 5-pillar Nov 22, 2026 | |
| $37.82 Nov 20, 2026 | $167B | 87 5-pillar Nov 22, 2026 | |
| $150.47 Nov 20, 2026 | $284B | 83 5-pillar Nov 22, 2026 | |
| $99.94 Nov 20, 2026 | $128B | 82 5-pillar Nov 22, 2026 | |
| $310.00 Nov 20, 2026 | $118B | 81 5-pillar Nov 22, 2026 | |
| $101.10 Nov 20, 2026 | $19.1B | 80 5-pillar Nov 22, 2026 | |
| $28.61 Nov 20, 2026 | $28.0B | 79 5-pillar Nov 22, 2026 | |
| $41.98 Nov 20, 2026 | $60.9B | 77 5-pillar Nov 22, 2026 | |
| $339.85 Nov 20, 2026 | $305B | 76 5-pillar Nov 22, 2026 | |
| Abbott Laboratories (ABT) — this page | $103.00 | $178B | 71 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $112.00 – $130.00
- Consensus target
- $120.85
- Median target
- $120.00
Consensus record · Captured .
Measured against a quoted price of $103.00 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 5, 2026
- Transactions
- 25
- Identified insiders
- 11
- Purchases
- 0
- Sales
- 5
- Other transactions
- 20
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ABT in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ABT in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Abbott Laboratories (ABT)?
What Investors Ask About Abbott Laboratories (ABT) — Healthcare
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why is Abbott not simply a medical-device company?
Abbott’s largest segment is Medical Devices, but the company also earns substantial revenue from Diagnostics, Nutrition, and Established Pharmaceutical Products. Its headline results therefore combine device adoption with laboratory testing, nutritional demand, and medicine sales.
Why did Abbott’s latest revenue gain not lift operating profit?
Gross profit increased, but selling, general and administrative expense rose sharply and research spending also moved higher. Those expenses more than absorbed the incremental gross profit, leaving operating profit below the preceding period.
What does Abbott’s Established Pharmaceutical Products segment add to the business mix?
The segment supplies generic medicines across a broad set of conditions, adding a pharmaceutical demand stream alongside devices, diagnostics, and nutrition. It makes Abbott’s consolidated sales less dependent on medical procedures alone.
How does Abbott’s falling cash balance fit with positive operating cash flow?
Positive operating cash generation and a declining cash balance can coexist when cash uses elsewhere exceed the period’s inflow. For Abbott, the important observation is that operating cash flow remains positive while cash and short-term investments have moved lower and debt remains materially larger than liquidity.
What is the ABT stock price today?
The last price recorded for Abbott Laboratories (ABT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ABT price target?
The analyst consensus price target for Abbott Laboratories (ABT), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 51 figures on this page — 1 from SEC filings and earnings calls, 45 from Financial Modeling Prep (FMP), 2 with no recorded source, 1 computed by us, formula shown in the register and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold ABT
Funds in our ETF coverage that list ABT among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| VHT ETF | 2.90% | |
| ProShares - Ultra Health Care (RXL) | 2.48% | |
| IXJ ETF | 2.44% |
